Skip to main content
Clinical Trials/NCT03671629
NCT03671629
Recruiting
N/A

Involving Clinical Pharmacists in Transitional Care to Reduce Drug-related Readmissions Among the Elderly - a Randomized Controlled Trial

Umeå University1 site in 1 country700 target enrollmentSeptember 19, 2018
ConditionsDrug Use

Overview

Phase
N/A
Intervention
Not specified
Conditions
Drug Use
Sponsor
Umeå University
Enrollment
700
Locations
1
Primary Endpoint
Time from discharge to first drug-related readmission
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

This randomized controlled trial primarily investigates if a clinical pharmacist intervention can reduce drug-related readmissions among patients >75 years. The intervention targets the transfer between hospital and primary care. In brief, the intervention includes medical chart reviews and patient interviews during a period of 180 days.

Detailed Description

At discharge from the hospital, patients that meet the inclusion criteria are offered to participate in the study. At this point the investigators will also gather baseline data through questionnaires on self-reported adherence (MARS-5) and quality of life (EQ-5D). The participants are randomized to the different study arms according to a stratified procedure based on their cognitive function. The intervention group will have their charts reviewed every second week and be contacted by the clinical pharmacist through phone within 7 and after 30 and 60 days respectively to discuss their medications. If possible drug-related problems are suspected during the interviews that cannot be solved immediately, the physician is contacted. Both groups have a follow-up time of 30 and 180 days. After 30 and 180 days, the patients will once again report adherence and quality of life. All other data can be gathered from the medical charts.

Registry
clinicaltrials.gov
Start Date
September 19, 2018
End Date
December 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Maria Gustafsson

Principal Investigator

Umeå University

Eligibility Criteria

Inclusion Criteria

  • Living at home
  • Acutely admitted
  • Registered at one of ten pre-specified primary care health centers

Exclusion Criteria

  • Patients unable to communicate or who do not speak Swedish
  • Patients scheduled for palliative care
  • Patients admitted due to intoxication by alcohol or drug (non prescription)

Outcomes

Primary Outcomes

Time from discharge to first drug-related readmission

Time Frame: 180 days

Survival analysis with drug-related readmission as endpoint

Secondary Outcomes

  • Time from discharge to first drug-related readmission(30 days)
  • Frequency of drug-related readmissions - subgroups with/without heart failure(30 and 180 days)
  • Time from discharge to first all-cause hospital visit(30 and 180 days)
  • Frequency of drug-related readmissions(30 and 180 days)
  • Time from discharge to first drug-related readmission - subgroups with/without cognitive impairment(30 and 180 days)
  • Frequency of drug-related readmissions - subgroups with/without cognitive impairment(30 and 180 days)
  • Self-reported adherence(30 and 180 days)
  • Mortality(30 and 180 days)
  • Time from discharge to first drug-related readmission - subgroups with/without heart failure(30 and 180 days)
  • Frequency of all-cause hospital visits(30 and 180 days)
  • Self assessed quality of life: EQ-5D-questionnaire(30 and 180 days)
  • Health economics(180 days)
  • Medication appropriateness(180 days)

Study Sites (1)

Loading locations...

Similar Trials